{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Olaf", "organization": "", "rank": 1, "lastname": "STORBECK"}, {"role": "reported", "firstname": "Kevin", "organization": "", "rank": 2, "lastname": "ALLISON"}], "original": "By OLAF STORBECK and KEVIN ALLISON"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "A Bayer-Monsanto Tie-Up Could Be a Bitter Pill"}, "print_page": null, "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Monsanto Company", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Bayer AG", "is_major": "N", "rank": "3", "name": "organizations"}], "snippet": "Amid reports of an offer, analysts look at the numbers to determine how a deal would work.", "source": "The New York Times", "lead_paragraph": "Amid reports of an offer, analysts look at the numbers to determine how a deal would work.", "word_count": "392", "pub_date": "2016-05-13T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/05/13/business/dealbook/a-bayer-monsanto-tie-up-could-be-a-bitter-pill.html", "_id": "5734d07b38f0d878c2872d7a"}